- 1 Title: Costs and outcomes of routine HIV oral pre-exposure prophylaxis 2 implementation across different service delivery models and key populations 3 in South Africa
- 4

5 Authors:

Order	Name	Email	Preferred degree	Affiliation
1	Cheryl Hendrickson	chendrickson@heroza.org	MPH	a, b
2	Kamban Hirasen	khirasen@heroza.org	MA	а
3	Constance Mongwenyana	cmongwenyana@heroza.org	MA	а
4	Mariet Benade	mbenade@bu.edu	MBChB	с
5	Rutendo Bothma	rbothma@wrhi.ac.za	MPH	d
6	Chantal Smith	csmith@match.org.za	MBChB	e
7	Johan Meyer	meyerj@out.org.za	BA Theology	f
8	Brooke Nichols	brooken@bu.edu	PhD	a, b, c
9	Lawrence Long	lclong@bu.edu	PhD	a, c

6

7 **Affiliations:**

8 ^a Health Economics and Epidemiology Research Office, Faculty of Health Sciences, University of the 9 Witwatersrand, Johannesburg, South Africa

10 11

12

13

15

17

19

^b Department of Medical Microbiology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands

14 ^c Department of Global Health, Boston University School of Public Health, Boston, MA, USA

16 ^d Wits RHI, University of the Witwatersrand, Johannesburg, South Africa

18 ^e MatCH Maternal, Adolescent and Child Health Institute, KwaZulu-Natal, South Africa

20 ^f OUT LGBT Well-Being, Johannesburg, South Africa

21		
22	Running title:	Cost and outcomes of PrEP in SA
23		
24	Address correspondence:	Cheryl Hendrickson
25		chendrickson@heroza.org
26		32 Princess Terrace
27		Parktown, 2193
28		Johannesburg, South Africa.
29		

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

30 31 32 33	Supported by:	USAID 72067419CA00004 LL time NIMH K01MH119923 CH time D43 TW010543
34 35 36	Key words:	South Africa, HIV, pre-exposure prophylaxis, costs and cost analysis
37	Word count:	3812

All rights reserved. No reuse allowed without permission.

38 Abstract

39

Background: Oral pre-exposure prophylaxis (PrEP) is a highly efficacious biomedical HIV prevention tool, yet despite being recommended by the World Health Organization (WHO) since 2015, uptake and persistence remain limited in much of the world, including sub Saharan Africa (SSA). There is a dearth of evidence-based interventions to improve PrEP uptake and persistence in SSA, and the full costs of PrEP programs implemented in routine care settings remain largely unknown. This study aimed to evaluate the cost of delivery of daily oral PrEP, and associated outcomes, to different key and priority populations across different service delivery models (SDMs) in South Africa.

47

48 Methods: We conducted bottom-up micro-costing of PrEP service delivery from the provider 49 perspective within twelve urban SDMs providing routine PrEP services to various key and propriety 50 populations in Gauteng and KwaZulu-Natal provinces in South Africa. The SDMs included in-facility 51 and outreach models that focused on men who have sex with men (MSM), female sex workers (FSW) 52 and adolescent girls and young women (AGYW). We identified all within- and above-facility activities 53 supporting PrEP delivery, obtained input costs from program budgets, expenditure records and staff 54 interviews, and determined individual resource usage between February 2019 and February 2020 55 through retrospective medical record review. Our primary outcome was PrEP coverage at six months 56 (defined as having sufficient PrEP drug dispensed at the last visit to be covered at six months post 57 PrEP-initiation). A subset (N=633) of all enrolled subjects had the potential for 12 months of follow-58 up and were included in a 12-month outcome analysis. We report the cost per client initiated on PrEP 59 in 2021 United States Dollars (USD).

60

61 Findings: We collected medical record data from 1,281 people who initiated PrEP at 12 SDMs between 62 February and August 2019 and had at least six months of potential follow-up. The average number of 63 visits was 2.3 for in-facility models and 1.5 for outreach models and 3,086 months of PrEP was 64 dispensed. PrEP coverage at six months varied greatly across SDMs, from 41.8% at one MSM-focused 65 fixed clinic to 0% in an MSM-focused outreach model. In general, in-facility programs had higher six-66 month coverage than outreach programs. Across all SDMs with PrEP clients with potential for 12 67 months of follow-up (n=633), PrEP coverage at 12 months was 13.6%, with variability between SDMs. 68 The average six-month cost per client initiated on PrEP ranged from \$29 to \$590, with higher average 69 costs generally observed for the in-facility programs (\$152 in-facility versus \$84 for outreach). The 70 average monthly cost per PrEP client who had six-month PrEP coverage ranged from \$18 to \$160 71 dependent on SDM.

- 72
- 73 Interpretation: This study is an important addition to the PrEP outcome and cost literature in the SSA 74 region. Results show that costs and outcomes vary considerably across different SDMs and 75 populations in real world PrEP programs and provide crucial information for further scale-up of the 76 oral PrEP program in South Africa and the greater SSA region. 77 78 Word count (abstract): 483
- 79

All rights reserved. No reuse allowed without per

80 **Research in context**

81

82 Evidence before this study

83 Although there have been several modelling studies conducted to investigate the cost and cost 84 outcomes of pre-exposure prophylaxis (PrEP) in sub Saharan Africa, there is a dearth of evidence on 85 the real-world costs of providing PrEP in this region. A search of PubMed conducted before 86 commencement of this study using the terms "PrEP" AND "cost analysis" AND "sub Saharan Africa" 87 for studies published in English between 2016 and 2022 along with the exclusion of publications whose 88 results stemmed from models or that were irrelevant, showed that only nine studies covering four 89 countries have been published that present primary costs of PrEP in this region. Those that have been 90 published generally focus on one population group, are costing particular interventions in a research 91 setting or only use ingredients-based methodology without associated outcomes.

92

93 Added value of this study

We include cost and cost outcomes from a large cohort of PrEP-clients who initiated PrEP across twelve models of care and have at least six months of potential follow-up. Costs are based on actual individual resource utilization data and program expenses, which differentiate it from modelling and ingredients-based costing studies. These results add to the growing body of evidence on the outcomes and associated costs of routine implementation of PrEP programs in the sub Saharan African region, which can be used to strengthen budget impact analyses which will, in turn, assist policy makers in program scale up decisions.

101

102 Implications of all the available evidence

This study provides evidence needed to inform the scale up of PrEP service delivery models. Through the micro-costing approach across several service delivery models, we cost the real-world implementation of these models, which will feed into the evidence needed for HIV prevention scale up and budget planning in South Africa and the wider SSA region. Estimates of provider costs for large scale, routine, effective PrEP delivery platforms that take into account economies of scale, changes in marginal costs as programs expand, understanding the differences in costs and benefits for different populations and risk groups will be vital to the success and sustainability of PrEP programs in SSA.

110 Introduction

The HIV epidemic continues to impact millions of people globally, particularly in sub Saharan Africa (SSA), where 60% of new infections occurred in 2020 (1). South Africa is particularly hard hit, with an estimated 210,000 new HIV infections in 2021 and an HIV incidence of 4.19 per 1,000 population (2). Progress on the prevention of HIV infection remains largely stagnant; the global annual number of new infections among adults has hardly changed over the past four years, with the total new infections having declined by 38% from 2.1 million (1.6 million-2.8 million) in 2010 to 1.3 million (1 million-1.7 million) in 2022 (1, 3). This is far short of the 2016 United Nations General Assembly target of 75% for

118 2020 (4).

119 Pre-exposure prophylaxis (PrEP) is a highly effective biomedical HIV prevention tool, reducing the risk 120 of HIV-1 acquisition by more than 95% in studies with high adherence (5). However, there are still 121 substantial gaps in the availability of PrEP, with the total number of people using this prevention 122 option at just 28% of the 2020 UNAIDS target of 3 million individuals accessing PrEP in low- and middle-123 income countries; and just 8% of the new global 2025 target (4, 6). South Africa adopted the World 124 Health Organization's recommendation to offer PrEP to those at "substantial risk of HIV infection" in 125 2016, beginning PrEP rollout to select key populations at pilot sites and expanding nationally 126 thereafter (7). Despite this national rollout, PrEP uptake has been slow, with approximately 106,400 127 people at risk of HIV infection who received PrEP at least once in 2020 (1). This has increased, with 128 almost 350,000 people receiving PrEP in 2021 (2); however, these numbers are still suboptimal. Until 129 recently, the PrEP drug procurement program had been mostly donor funded, however, this is 130 changing such that the South Africa PrEP program is now largely government funded. As South Africa 131 continues to scale-up PrEP provision, data are needed to inform the total cost and affordability of the 132 various service delivery models (SDMs). There is little information, however, to support evidence-133 based resource allocation decisions in the public sector thus far.

134

135 Several modelling studies have investigated the cost-effectiveness of PrEP provision in SSA, and the 136 results are mixed, with large variations in assumed costs of PrEP provision (8-14). Similarly, in South 137 Africa, modelling studies also present results that only show cost-effectiveness under certain 138 conditions such as population-targeted programs, whether PrEP-clients self-select or have high 139 assumed rates of uptake and persistence. These results are largely dependent on the cost estimates 140 used as well as the assumptions around PrEP uptake and persistence (15-20). While modelled 141 estimates provide useful approximations, the most accurate cost estimates are based on actual client 142 resource usage in routine implementation and are critical to determining true cost-effectiveness.

144 An understanding of the true resource utilization, cost, and expected outcomes of different PrEP 145 service delivery models in South Africa is currently lacking. We have therefore conducted a cost 146 outcomes study to evaluate the cost of delivering daily oral PrEP to different populations across 147 different SDMs in South Africa by estimating the average cost and associated outcomes of PrEP 148 provision in routine settings. These results may serve to inform the expansion of PrEP programs both 149 within South Africa and the greater SSA region and to provide evidence on how to optimize service 150 delivery to improve cost-effectiveness and provide data to conduct budget impact analyses for future 151 policy decisions and implementation strategies in HIV prevention programming.

152

153 Methods

154

155 Study sites and population

156 We conducted bottom-up micro-costing of PrEP service delivery within twelve urban SDMs providing 157 routine PrEP services in Gauteng and KwaZulu-Natal provinces in South Africa. These models 158 comprised of PrEP services delivered by seven public, multiservice clinics, specialized clinics and 159 community outreach programs, including Technical and Vocational Education and Training colleges 160 (Table 1). Most of the seven sites had both an in-facility and an out-reach model, while some sites 161 were limited to a single model of PrEP provision. The selected SDMs were focused on reaching specific 162 populations considered to be at increased risk for HIV acquisition, including female sex workers (FSW), 163 men who have sex with men (MSM), adolescent girls and young women (AGYW) as well as students 164 at tertiary institutions. All PrEP service delivery was provided per South African national guidelines 165 (21). We intentionally selected SDMs that had been routinely providing PrEP for at least nine months 166 prior to data collection and that had initiated at least 25 people on PrEP with at least six months of 167 potential follow-up prior to data collection.

168

169 We enrolled a cohort of clients screened for HIV, found eligible for, and initiated on PrEP, and with at 170 least six months of potential follow-up time between February 2019 to February 2020. We included 171 PrEP-clients who were \geq 18 years old and who were recorded as having initiated PrEP within the 172 respective SDM. We excluded PrEP-clients who had missing files, incomplete data, or if they had been 173 transferred out of PrEP care at the selected site within six months of PrEP initiation. Although models 174 focused on specific populations, we did not limit enrolment based on target population. For example, 175 a program focused on MSM may have provided services to a male who did not identify as MSM and 176 this man would have been eligible for inclusion in the costing cohort providing they met the other 177 inclusion/exclusion criteria.

All rights reserved. No reuse allowed without permission.

178

179 There was no contact with any of the PrEP-clients whose data were used in the study. Data on their 180 medical history, enrolment into PrEP and resource usage during the follow-up period since PrEP 181 initiation was retrospectively extracted from routine client medical records. Within each SDM, we 182 enrolled the most recently initiated PrEP clients who had at least six months of potential follow-up 183 post PrEP initiation. The target enrolment per study population and service delivery model was 200, 184 based on a t-test for sample means, using modelled results of cost estimates for PrEP service delivery 185 in South Africa (16). We estimated that with this sample size, an alpha error rate of 0.05 and 80% 186 power, we would be able to detect at least a 10% difference in cost between SDMs, provided the 187 standard deviation did not exceed 25% of the current modelled cost.

188

189 Data Collection

190 Routinely collected client-level data from clients' medical records, including hard copy client files, and 191 both hard copy and electronic client registers, were extracted and managed using REDCap electronic 192 data capture tools hosted at the University of Witwatersrand (22, 23). These data provided individual 193 resource utilization, such as number of clinic visits, service and medications provided, and laboratory 194 tests performed. Facility-level data, such as client headcounts, were extracted from clinic registers. 195 Client-level data for the period February 2019 to February 2020 were collected from September 2020 196 to March 2021. Facility-level data for the 2019 calendar period were collected from February to August 197 2021.

198

199 Costing

200 We estimated the economic costs of PrEP provision from the provider perspective using previously 201 described micro-costing methods (24, 25). We used routine client records to estimate resource 202 utilization for each client over the study period and then multiplied the resource usage by the unit 203 cost. Specific methods and sources for the unit costs for drugs, laboratory tests, clinical staff time, 204 buildings and equipment as well as management and administration costs are shown in Table 2. 205 Resources captured included drugs, diagnostic and laboratory tests, clinical staff time, buildings, 206 equipment, supplies and other shared services, such as utilities and non-clinical staff time. Shared 207 resource costs were collected using facility-level financial records as well as price lists from suppliers 208 and these were proportionally allocated according to the fraction of total visits that were dedicated 209 to PrEP provision. Above site-level management staff salaries were excluded from the main analysis. 210 We collected all costs in South African Rand (ZAR) and inflated the costs to 2021 prices (where 211 necessary) using the South African Consumer Price Index (26). Costs are reported in United States

Dollars (USD) using the average 2021 exchange rate of 14.78 ZAR:USD and we assumed a useful life offive years for all capital items (27).

214

215 Outcomes

Our primary outcome (PrEP coverage at six months) for this study was defined as having sufficient PrEP drug dispensed at the last visit to be covered at six months post PrEP-initiation. PrEP outcomes available from routine medical records are difficult to interpret as they do not typically speak directly to adherence. To help understand what is happening in each program we report a number of additional outcomes (same-day initiation, engagement in care, time in care) at various time points, if available. Nine and twelve month outcomes were only reported from the subset of sites that had PrEP clients with 12-months of follow-up. Definitions of each outcome are reported in Table 3.

223

224 Data Analysis

225 All enrolled study participants were included in a six-month cost and outcome analysis. A subset 226 (N=633) of all enrolled subjects across eight SDMs had the potential for 12 months of follow-up and 227 were included in a 12-month outcome analysis. We describe baseline characteristics and outcomes 228 across the study sites, SDM and study population. We also estimated average PrEP-client resource 229 utilization over the six-month study period and the average cost per PrEP-client by SDM and primary 230 outcome and disaggregated by cost category (drugs, laboratory testing, visit costs and fixed costs). 231 Aggregate results are presented in the text, while results disaggregated by site and SDM are reported 232 in the text and tables. Additionally, we also estimated the production cost, a calculation that takes the 233 costs of services to all clients and divides it by only those achieving the primary outcome of PrEP 234 coverage at six months post PrEP-initiation; this incorporates effectiveness into the cost estimates. 235 We also conducted an additional analysis to estimate an average 'above site' management cost that 236 can be used as an estimate of costs across the SDMs. All analyses were conducted in Excel (Microsoft 237 Office Standard 2019) using the Healthcare Cost and Outcomes Model to estimate the cost per patient 238 (28) and Rstudio version 1.4.1106.

239

240 Ethics approval

This study was approved by the Human Research Ethics Committee (Medical) of the University of the Witwatersrand (M190621) and the Boston University IRB (H-39120). Data was collected retrospectively and a waiver of informed consent was granted by the ethics review boards.

- 244
- 245 **Results**

All rights reserved. No reuse allowed without permission.

246

247 Sample characteristics

248 We collected data from 1,281 people who initiated PrEP between February and August 2019 across 249 seven sites and 12 SDMs, about half (633/1281) of whom had the potential for 12 months of follow-250 up across eight of the SDMs (Table 4). This included 1,281 initiation visits and 1,245 follow-up visits 251 amounting to more than 3,000 months of PrEP dispensed. The majority of PrEP-clients were initiated 252 in 2019 (994/1281, 77.6%) while the remainder initiated in 2018. On average, participants were young, 253 with a median age of 27 (IQR: 23-33); this was even lower among the AGYW-focused outreach 254 programs which had a median age of 22 (IQR: 21.0-24.8). About a sixth (63.7%) of PrEP-clients were 255 female with the sex distribution largely influenced by the population the site focused on; however, 256 8.3% (74/889) of the PrEP initiates at the FSW- and AGYW-focused programs were male.

257

258 In general, the SDMs largely served the population group that they were focusing on (i.e. an MSM-259 focused program mostly initiated MSM clients on PrEP); however there is variability in population 260 within sites and SDMs. The MSM-focused outreach programs reported that one in five initiates 261 identified as heterosexual men (40/192, 20.8%) compared to the in-facility MSM programs which 262 reported only 1.5% heterosexual males (3/200, 1.5%). Other SDMs showed more heterogeneity in 263 their PrEP-client populations, with the AGYW in-facility sites initiating older women (aged \geq 25, 264 114/368, 31.0%), FSW (2/368, 0.5%), heterosexual males (22/368, 6.0%) and one MSM in addition to 265 the 60.1% AGYW. The AGYW outreach sites were similar, with the majority of PrEP initiates in the 266 AGYW population category (51/90, 56.7%); however, almost one in five persons (17/90, 18.9%) 267 initiated on PrEP were women older than 24 years of age as well as five? (5.6%) heterosexual males. 268 In this AGYW outreach group 16/90 (17.8%) did not indicate which population group they were in. The 269 FSW sites largely initiated FSW (106/138 (76.8%) in-facility and 275/293 (93.9%) outreach); however, 270 a few AGYW, MSM and Transgender women also initiated at these FSW-focused programs.

271

We observed variability across sites and SDMs on PrEP-clients indication for PrEP, with most sites and SDMs showing a combination of PrEP-clients both initiating PrEP at their request and due to formal risk assessments. However, some were more skewed, for example one MSM-focused outreach model (MSM Site 2) indicated that almost all clients (132/139,95.0%) requested PrEP, while one FSW-focused outreach model (FSW Site 3) had the inverse with the majority (77/96, 80.2%) initiated based on the risk assessment. Within most SDMs, almost all PrEP-clients (1191/1281, 93.0%) had a formal risk assessment done prior to, or at, PrEP initiation. Exceptions to this were the two MSM-focused outreach programs (Site 1: 86.3% and Site 2: 54.7%), the FSW-focused clinic (84.4%) and outreach
(86.7%) (Site 3) and the TVET-focused outreach program (Site 6, 86.7%).

281

282 Resource utilization and unit costs

283 The average six-month resource utilization by site and service delivery model is shown in Table 5. In 284 general, there was higher resource utilization in the in-facility SDMs than in the outreach SDMs. The 285 average number of visits was 2.3 (standard deviation (SD) of 1.7) for the in-facility models and 1.5 (SD: 286 1.0) for the outreach models. This varied for the specific sites, with MSM Site 2 (in-facility) having the 287 highest average number of visits of 3.0 (SD: 1.5) and the affiliated outreach program having the lowest 288 at 1.0 (SD: 0.1) over the six month period. Across all population groups, the average number of days 289 PrEP was dispensed was higher in the in-facility models (mean: 83, SD: 65) than in the outreach models 290 (mean: 51, SD: 42); this difference between models was greatest among the MSM-focused programs 291 with the outreach programs having the least PrEP dispensed on average (mean: 32; SD: 15) and in-292 facility having the most (mean: 124; SD: 61). Drug dispensing for sexually transmitted infections and 293 other conditions were also observed, with 121 (9.4%) of PrEP-clients receiving STI treatment and 221 294 (17.3%) receiving other medication during the first six months post PrEP initiation. Higher proportions 295 of PrEP-clients received STI treatment in the FSW-focused models (14.1-33.3%) compared to the 296 AGYW-focused models (0-4.2%). The mean number of HIV tests administered over the six months post 297 PrEP initiation was 1.87 (SD: 1.22) and 1.43 (SD: 0.84) for in-facility and outreach models respectively. 298 About one creatinine test was done per PrEP-client over the same period, while the other laboratory 299 tests were done less frequently.

300

301 PrEP-client outcomes

302 Overall, the majority (1,191/1,281, 93.0%) of PrEP-clients initiated PrEP the same day as their negative 303 HIV test. One notable exception was the MSM-focused clinic (Site 1), where only a third (32/98, 32.7%) 304 of clients were same-day initiators (Table 6). The proportion of PrEP-clients returning for at least one 305 follow-up visit varied greatly, from only 1.9% at one MSM-focused outreach program to 90.5% at an 306 FSW-focused clinic. Similarly, time in care at six months ranged from an average of 28.9 days (SD: 8.2) 307 to 126 (SD: 61.2) across sites. Our primary outcome, PrEP coverage at six months, varied greatly across 308 SDMs, but was low overall; the highest coverage observed was in an in-facility program focused on 309 reaching MSM (41.8%) while an MSM-focused outreach program had no PrEP-clients with coverage 310 at six months. In general, in-facility programs had higher six-month coverage than the outreach 311 programs, with the exception of one of the FSW-focused programs where the outreach program had 312 a higher coverage (22.4%) compared to the in-facility program (13.5%). The AGYW-focused programs

had low coverage, ranging from 4.4% to 15.5% at six months. Three clients (two at an FSW-focused
clinic and one at an AGYW-focused clinic) acquired HIV during the study six-month follow-up period.

- Similar patterns are observed among the PrEP clients with 12 months of potential follow-up (n=633), with average time in care ranging from 41 days (SD: 42) to 221 (SD: 127). Across all included programs, PrEP coverage at 12 months was 13.6% (86/633), with variability across sites and programs. The MSMfocused clinic had 12-month PrEP coverage of 35.1%, while its accompanying outreach program had no PrEP-clients with this coverage. The two FSW-focused clinics and outreach programs ranged from 9.7% to 19.5% coverage at 12 months, while the AGYW-focused site had 4.4% and 6.1% coverage for the in-facility and outreach programs respectively.
- 323

324 Costs and cost outcomes

325 When considering all included clients initiated on PrEP, the average cost per PrEP-client ranged from 326 \$29 for an MSM-focused outreach program to \$590 for an FSW-focused in-facility program, with 327 higher average costs generally observed for the in-facility programs (Table 7). When estimating the 328 costs for only those who achieved the primary outcome (PrEP coverage at six months), the average 329 cost per PrEP client ranged from \$108 at one of the FSW-focused outreach programs to \$959 at an 330 FSW-focused in-facility program. Overall, the in-facility programs resulted in higher average costs per 331 PrEP client compared to the accompanying outreach program. This trend held when considering the 332 average cost per PrEP-client among those with PrEP coverage at six months, with the in-facility 333 programs ranging from \$159 to \$920 and the outreach programs from \$108 to \$220 over six months. 334 While the average costs might have been lower for outreach programs, the production costs, or six-335 month costs to produce one client with six-month PrEP coverage were, on average, much higher. The 336 exception to this were the FSW-outreach programs which had lower production costs than the 337 corresponding in-facility programs.

338

339 **Discussion**

340

In this micro-costing study, we estimated the real-world outcomes and costs of PrEP provision across seven sites that made up 12 SDMs reaching MSM, FSW and AGYW populations. The costs of six months of PrEP provision varied widely across sites and service delivery models from \$29 to \$590 per client initiated and \$108 to \$959 among those who achieved PrEP coverage at six months. These costs were largely driven by clinic personnel and fixed costs, which is similar to costs published from other studies in the region (29-31). Meyer-Rath et al. (32) used an ingredients-based approach relying on expert

347 opinion, available literature and several assumptions to estimate the cost per client year for the first 348 year on PrEP for young women in South Africa, obtaining an estimate of approximately US\$124; no 349 specific SDM was indicated. This is generally lower than estimated through this costing of real-world 350 service delivery, highlighting the importance of micro-costing in providing a more granular view of 351 costs and associated outcomes of PrEP provision, which is key for future program, intervention and 352 budget planning. When compared to the published costs of providing PrEP in other micro-costing 353 studies done in the region, the costs observed in these SDMs are generally higher, with annual costs 354 ranging from \$92 to \$943 per year in these studies (31, 33-39). Two possible explanations for these 355 differing results are the more extensive inclusion of programmatic costs and relatively low PrEP client 356 volumes in the SDMs with particularly high costs. Some of the SDMs were still within their first year 357 or two of PrEP provision and this may have contributed to both low client volumes and low PrEP 358 persistence as models were still learning how to effectively promote PrEP among those who might 359 benefit from it.

360

Overall, in-facility programs were costlier per person on PrEP than the outreach programs, however, they generally had better PrEP coverage at six months, resulting in lower production costs. A notable exception to this were the FSW outreach programs which had lower production costs than the infacility programs, highlighting the need for differentiated programs that focus on PrEP-client needs – in this case, PrEP service delivery offered at the FSWs places of work. Some of the high costs can be attributed to the low PrEP-client volume and we observe patterns of lower costs with higher client volumes. This could indicate potential for economies of scale for these programs.

368

369 Across all sites and service delivery models we observed low PrEP coverage over time, ranging from 370 0% to 50% at six months post PrEP initiation. This is in line with other literature from the region (31, 371 40). This is concerning given that these groups are disproportionally affected by HIV. AGYW accounted 372 for 25% of new HIV infections in 2020, despite representing just 10% of the population in SSA with an 373 estimated 4,200 AGYW infected with HIV every week in 2020 (1, 6). Additionally, in 2020, key 374 populations (sex workers and their clients, gay men and other men who have sex with men, people 375 who inject drugs, transgender people) and their sexual partners accounted for 65% of HIV infections 376 globally, and accounted for 39% of new HIV infections in sub-Saharan Africa (6). The associated costs 377 presented here will be helpful in future budget planning for interventions aimed at improving the low 378 PrEP coverage among populations at risk of HIV acquisition in the SSA region.

380 There are several limitations in this study. Firstly, the limited information available around ongoing 381 risk in the PrEP cohort limits any conclusions about who is persisting versus discontinuing on PrEP. 382 Risk assessments were not captured at all visits and the reasons for stopping PrEP and changes in risk 383 cannot be determined. Therefore, apart from three clients who seroconverted during the six month 384 follow-up period, it is not known whether PrEP-client changes in outcomes were due to changes in 385 risk, adoption of other HIV prevention mechanisms or simply discontinuation of PrEP with no change in HIV acquisition risk. Additionally, the documentation of risk or reason for PrEP initiation at first visit 386 387 was not standardized and, as such we are unable to say whether these programs were initiating the 388 people who would most benefit from being on PrEP. We were also not able to trace the movement of 389 clients from one site or model to another. We therefore are not able to accurately distinguish transfer 390 of PrEP care to another facility from loss-to-follow-up. With regards to costing, demand creation 391 efforts were not captured in a systematic and measurable way so we are unable to differentiate those 392 costs from the broader fixed costs of the program. Additionally, we only captured resource utilization 393 from the point of PrEP initiation, so we are unable to attribute any costs associated with PrEP demand 394 creation and screening at the individual level. It is becoming increasingly clear that these are important 395 components of PrEP provision programs that need to be included when considering PrEP program 396 scale-up.

397

398 Despite these limitations, our study is an important addition to the PrEP cost literature in the SSA 399 region, providing vital outcome and unit cost data on real world PrEP provision in South Africa across 400 a diverse set of service delivery models and populations. These data may be used to strengthen budget 401 impact and cost-effectiveness analyses, providing crucial information for further scale-up of the oral 402 PrEP program in South Africa and the greater SSA region.

403 Acknowledgements

We are grateful to the men and women who contributed their data to this study. We thank the implementing partners and clinic staff for their time and efforts in providing us with the data required to carry out this analysis. Additionally, we thank the study staff (Nkamoheleng Mokhesi, Nonhlanhla Tshabalala, Portia Ngwenya, William Magolego and Lerato Molapo) for their excellent assistance in data collection.

409

410 **Funding**

411 This study has been made possible by the generous support of the American People and the 412 President's Emergency Plan for AIDS Relief (PEPFAR) through US Agency for International 413 Development (USAID) under the terms of Cooperative Agreement 72067419CA00004 to HE²RO. CH 414 was supported by the Fogarty International Center and National Institute of Mental Health through 415 the National Institutes of Health award number D43 TW010543. LL was supported by the National 416 Institute of Mental Health of the National Institutes of Health award number K01MH119923. The 417 contents are the responsibility of the authors and do not necessarily reflect the views of PEPFAR, 418 USAID, NIH or the US Government.

419

420 **Competing interests**

421 All authors declare that they have no competing interests.

422

423 Author contributions

424 CH and LCL led conception of the manuscript, design as well as drafting the manuscript, data analysis 425 and interpretation of results with contributions from KH, CM and MB. KH, CM and MB contributed to 426 the acquisition of the data, analysis and interpretation of the data and critical revision of the 427 manuscript. RB, JM, and CS contributed by providing site and resource utilization data. BN contributed 428 in the critical revision of the manuscript. All authors reviewed and approved the final version of the 429 manuscript.

430

431 Data sharing statement

432 The underlying individual level patient resource data and costs remain the property of the study sites.

433 On application to the study team specific site level and ethics approval can be obtained as required.

435 Figure legends

436 *No figures included*

437

Tables

Table 1: Site and service delivery model descriptions

Site	Delivery model	Management type	Location	Services offered	Population targeted	PrEP program start date	Total 2019 patient volume	Total 2019 PrEP volume	Proportion PrEP
MSM Site 1	Standalone specialised clinic	NGO	Johannesburg, Gauteng	PrEP, HCT, HIV treatment (ARV) and management, STI screening and treatment, TB screening and referral, Sexual health and lifestyle education and awareness; Community workshops and events; Provision of services at events and venues	MSM	2019	1681	716	43%
MSM Site 1	Mobile outreach	NGO	Johannesburg, Gauteng	PrEP, HCT, HIV treatment (ARV) and management, STI screening and treatment, TB screening and referral, Sexual health and lifestyle education and awareness; Community workshops and events; Provision of services at events and venues	MSM	2019	19966	728	4%
MSM Site 2	Standalone specialised clinic	NGO	Tshwane, Gauteng	PrEP, HCT, HIV treatment (ARV) and management, STI screening and treatment, TB screening and referral, Sexual health and lifestyle education and awareness; Community workshops and events; Provision of services at events and venues	MSM	2017	4720	1908	40%
MSM Site 2	Mobile outreach	NGO	Tshwane, Gauteng	PrEP, HCT, HIV treatment (ARV) and management, STI screening and treatment, TB screening and referral, Sexual health and lifestyle education and awareness; Community workshops and events; Provision of services at events and venues	MSM	2017	3705	942	25%
FSW Site 1	Standalone specialised clinic	NGO	Johannesburg, Gauteng	PrEP, ART, STI's, Family Planning, TB and HCT	SW	2015	1339	424	32%
FSW Site 1	Mobile outreach	NGO	Johannesburg, Gauteng	PrEP, ART, STI's, Family Planning, TB and HCT	SW	2015	16535	1253	8%
FSW Site 2	Standalone specialised clinic	NGO	Tshwane, Gauteng	PrEP, ART, STI's, Family Planning, TB and HCT	SW	2015	632	159	25%
FSW Site 2	Mobile outreach	NGO	Tshwane, Gauteng	PrEP, ART, STI's, Family Planning, TB and HCT	SW	2015	10472	823	8%
FSW Site 3	Mobile outreach	NGO	Ekurhuleni, Gauteng	PrEP, ART, STI's, Family Planning, TB and HCT	SW	2015	9454	858	9%
AGYW Site 1	Community Health Center (CHC)	Government	eThekwini, KwaZulu-Natal	PrEP, ART, SRH, Maternal, Mental health, Youth services and Child Health	AGYW	2017	367811	3025	1%
AGYW Site 1	Outreach to TVET campuses	NGO	eThekwini, KwaZulu-Natal	PrEP, ART, SRH, Maternal, Mental health, Youth services and Child Health	Tertiary students	2017	2030	2030	100%
AGYW Site 2	Standalone specialised clinic	Government	eThekwini, KwaZulu-Natal	PrEP, ART, SRH, Maternal, Youth services and Child Health	AGYW	2017	47139	3294	7%

Abbreviations: MSM: Men who have sex with men; SW: Sex worker; AGYW: Adolescent girls and young women; PHC: primary healthcare; TVET: Technical and vocational educational training; NGO: Non-governmental organisation; PrEP: Preexposure prophylaxis; ART: antiretroviral therapy; SRH: Sexual and reproductive health; TB: Tuberculosis; HCT: HIV counselling and testing; STI: Sexually transmitted infection

Resource	Method for estimating cost	Item	Unit	Cost (USD)	Source
Drugs	Pre-exposure prophylaxis and other drugs dispensed per PrEP-client during the study period were extracted from the individual client's clinic record. The published national drug unit costs were applied to determine total drug cost per client.	TDF/FTC	Tablet	0.14	Master Procurement Catalogue
		HIV Rapid Screen Test	Test	3.05	
		HIV Serology	Test	3.82	
	Diagnostic tests included pregnancy tests, urine dipsticks, HIV tests.	Alanine Transaminase	Test	3.14	
	The actual number of tests performed per PrEP-client during the study period was extracted from the individual client's clinic record.	Hepatitis B Surface Ag Rapid	Test	8.71	
	The published unit cost per test was applied to determine the	Hepatitis B Surface Ab	Test	8.71	
Diagnostic and	laboratory cost per PrEP-client.	Urine Dipstick	Test	0.89	Department of Health
monitoring	All laboratory and monitoring tests after PrEP initiation were	RPR*	Test	1.48	National Laboratory
laboratory tests	performed off site by the National Health Laboratory Service. The	Treponema Hemagglutination	Test	5.95	price lists
	actual number of tests performed per PrEP-client during the study	Latex Test for Pregnancy	Test	2.33	
	period was extracted from the individual client's clinic record. The published unit cost per test was applied to determine the laboratory	BHCG Qualitative	Test	5.87	
	cost per PrEP-client.	Aspartate Transaminase	Test	3.14	
		Alanine Transaminase	Test	3.14	
		Haemoglobin	Test	1.25	
Clinical staff time for PrEP- client care	Clinical staff time was defined as including any doctor, nurse, and HIV lay counselor time spent with the PrEP-client. The clinical staff time cost was calculated by taking the total PrEP clinical staff cost per month and dividing it by the total PrEP visits to the clinic per month to get the average clinical staff cost per visit. Clinical staff salaries were obtained from the site and/or implementing partner salary scales for that cadre.	Not applicable (site specific)	N/A	N/A	Site and/or implementing partner salary scales

Table 2: Costing methods and unit costs

Buildings and equipment	The total floor space allocated to the PrEP program was calculated by measuring the PrEP care floor space and adding on a proportion of floor space shared by different services (i.e. waiting rooms). A market related average rental cost per square meter was applied to estimate the cost of the building. Electricity costs were obtained for the facility and applied by square meter. Water and effluent costs were not available for the facility and cost per square meter was estimated based on a similar building. The replacement cost of equipment was obtained and a working life of 5 years applied to obtain a cost per month. All PrEP specific equipment was included and a proportion of equipment from shared spaces was included. The building and equipment costs.	Not applicable (site specific)	N/A	N/A	Site and/or implementing partner financial records
Management and administration costs	All staff members who did not provide direct patient care but provided some support to the PrEP program (i.e. clinic manager, data clerks) were included. Staff salaries were obtained from published public sector salaries for that cadre. The cost of all general supplies (i.e. not related to a particular service) was obtained from facility financial reports. Management and administration costs were apportioned to each PrEP-client based on a per visit cost. All costs for management and administration incurred at the site level (i.e. the primary health clinic) were included. Costs incurred above the level of the site were excluded.	Not applicable (site specific)	N/A	N/A	Site and/or implementing partner financial records

Outcome	Definition	Time points
Same-day initiation (percentage)	Participant initiated PrEP on the day of presentation for HIV test. Participants that did not initiate on the same day would have had separate visits for HIV testing and PrEP initiation.	Singular
Engaged in care after PrEP initiation visit (percentage)	Participant attended at least one visit after PrEP initiation within the follow up period. This is a measure of short-term persistence. Many studies have reported rapid attrition after initiation, which this outcome measures.	Singular
Engaged in care (percentage)	Participant attended at least one visit at, or after, specific time point post PrEP initiation. This cannot be reported at 12 months as we did not collect any data related >12 months after PrEP initiation.	3, 6, 9 months
Time in care (days)	Total number of PrEP tablets dispensed during the follow up period. We excluded any tablets dispensed at the last visit which would have covered time outside the follow up period. For example, a participant has 5 visits within 12 months. At the first 4 visits a total of 300 tablets are dispensed. Visit 5 occurs at 330 days and 90 tablets are dispensed, but only 35 of those tablets are counted towards time in care. Time in care for this participant is 335 at 12 months.	6, 12 months
PrEP Coverage	At the PrEP client's last visit in the follow up period, they were dispensed sufficient drug to cover them to the end of the follow up period.	3, 6, 9, 12 months

		MSM	Site 1	MSM	Site 2	FSW	Site 1	FSW	Site 2	FSW Site 3	AGYW	Site 1	AGYW Site 2
		In-facility (n=98)	Outreach (n=139)	In-facility (n=102)	Outreach (n=53)	In-facility (n=96)	Outreach (n=98)	In-facility (n=42)	Outreach (n=99)	Outreach (n=96)	In-facility (n=168)	Outreach (n=90)	In-facility (n=200)
Potential for 12-month follow up	Yes (%)	97 (99.0)	71 (51.1)	0 (0.0)	0 (0.0)	93 (96.9)	98 (100)	41 (97.6)	99 (100.0)	0 (0.0)	68 (40.5)	66 (73.3)	0 (0)
Age at PrEP initiation	Mean (SD)	35.6 (11.5)	30.4 (8.0)	32.1 (9.5)	31.6 (8.3)	30.3 (6.1)	29.5 (5.5)	30.7 (7.6)	29.7 (6.7)	28.9 (6.2)	23.1 (7.5)	23.3 (5.3)	25.1 (6.92)
	Median [IQR]	34 [26, 42]	29 [25, 35]	30 [25, 36]	31 [25, 36]	30 [26, 35]	29 [26, 33]	30 [26, 34]	29 [25, 34]	28 [25, 32]	21 [17, 26]	22 [21, 25]	24 [19, 29]
Sex	Male (%)	98 (100.0)	139 (100.0)	101 (99.0)	53 (100.0)	16 (16.7)	7 (7.1)	0 (0.0)	4 (4.0)	0 (0.0)	27 (16.1)	16 (17.8)	4 (2.0)
	Female (%)	0 (0.0)	0 (0.0)	1 (1.0)	0 (0.0)	80 (83.3)	91 (92.9)	42 (100.0)	95 (96.0)	96 (100.0)	141 (83.9)	74 (82.2)	196 (98.0)
Population ^a	MSM (%)	92 (93.9)	61 (43.9)	94 (92.2)	10 (18.9)	6 (6.2)	4 (4.1)	0 (0.0)	4 (4.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.5)
	FSW (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	66 (68.8)	86 (87.8)	40 (95.2)	93 (93.9)	96 (100)	0 (0.0)	0 (0.0)	2 (1.0)
	AGYW (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2 (2.1)	0 (0.0)	0 (0.0)	2 (2.0)	0 (0.0)	111 (66.1)	51 (56.7)	110 (55.0)
	PWID, SDC, TGW, TGM or MSW (%)	2 (2.0)	0 (0.0)	3 (2.9)	1 (1.9)	0 (0.0)	3 (3.1)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.1)	0 (0.0)
	Heterosexual males (%)	1 (1.0)	40 (28.8)	2 (2.0)	0 (0.0)	2 (2.1)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	19 (11.3)	5 (5.6)	3 (1.5)
	Females >24 years of age (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	30 (17.9)	17 (18.9)	84 (42.0)
	Not indicated (%)	3 (3.1)	38 (27.3)	3 (2.9)	42 (79.2)	19 (19.8)	5 (5.1)	2 (4.8)	0 (0.0)	0 (0.0)	8 (4.8)	16 (17.8)	0 (0.0)
Year of PrEP initiation	2018 (%)	61 (62.2)	57 (41.0)	0 (0.0)	0 (0.0)	52 (54.2)	19 (19.4)	34 (81.0)	8 (8.1)	0 (0.0)	0 (0.0)	55 (61.1)	1 (0.5)
	2019 (%)	37 (37.8)	82 (59.0)	102 (100.0)	53 (100.0)	44 (45.8)	79 (80.6)	8 (19.0)	91 (91.9)	96 (100.0)	168 (100.0)	35 (38.9)	199 (99.5)
Indication for PrEP	Risk assessment by HCW (%)	34 (34.7)	6 (4.3)	81 (79.4)	9 (17.0)	42 (43.8)	65 (66.3)	9 (21.4)	33 (33.3)	77 (80.2)	120 (71.4)	52 (57.8)	165 (82.5)
	Requested by client (%)	62 (63.3)	132 (95.0)	16 (15.7)	29 (54.7)	31 (32.3)	30 (30.6)	33 (78.6)	65 (65.7)	13 (13.5)	48 (28.6)	27 (30.0)	34 (17.0)
	No reason provided (%)	2 (2.0)	1 (0.7)	5 (4.9)	15 (28.3)	23 (24.0)	3 (3.1)	0 (0.0)	1 (1.0)	6 (6.2)	0 (0.0)	11 (12.2)	1 (0.5)
Risk assessment completed prior to or at PrEP initiation	Yes (%)	95 (96.9)	120 (86.3)	100 (98.0)	29 (54.7)	81 (84.4)	85 (86.7)	42 (100.0)	99 (100.0)	95 (99.0)	168 (100.0)	78 (86.7)	199 (99.5)

Table 4: Characteristics of PrEP clients at PrEP initiation by site type and service delivery model (n=1,281)

^aMSM includes 8 participants who indicated that they are bisexual

2

4 Table 5: Six-month resource utilisation by site and service delivery model

													AGYW Site
	_	MSM S	ite 1	MSM S	lite 2	FSW	Site 1	FSW	Site 2	FSW Site 3	AGYW	Site 1	2
		In-facility	Outreach	In-facility	Outreach	In-facility	Outreach	In-facility	Outreach	Outreach	In-facility	Outreach	In-facility
6-month cohort (n=1,281)		(N=98)	(N=139)	(N=102)	(N=53)	(N=96)	(N=98)	(N=42)	(N=99)	(N=96)	(N=168)	(N=90)	(N=200)
Visits and healthcare worker intera	ctions												
Number of visits	Mean (SD)	2.7 (1.1)	1.0 (0.2)	3.0 (1.5)	1.0 (0.1)	1.6 (1.0)	1.9 (1.0)	3.1 (2.0)	2.2 (1.5)	1.7 (1.0)	2.1 (1.7)	1.3 (0.7)	2.2 (1.9)
Number of visits	Median [Q1, Q3]	3 [2, 3]	1 [1, 1]	3 [2, 4]	1 [1, 1]	1 [1, 2]	2 [1, 2]	3 [2, 5]	2 [1, 3]	1 [1, 2]	1 [1, 3]	1 [1, 1]	1 [1, 3]
Number of nurse interactions	Mean (SD)	2.7 (1.1)	1.1 (0.2)	3.0 (1.5)	1.1 (0.3)	1.6 (1.0)	1.9 (1.0)	2.9 (1.6)	2.2 (1.5)	1.7 (1.)	2.1 (1.7)	1.3 (0.7)	2.2 (1.9)
Number of nurse interactions	Median [Q1, Q3]	3 [2, 3]	1 [1, 1]	3 [2, 4]	1 [1, 1]	1 [1, 2]	2 [1, 2]	3 [2, 4]	2 [1, 3]	1 [1, 2]	1 [1, 3]	1 [1, 1]	1 [1, 3]
Number of counsellor interactions	Mean (SD)	2.6 (1.1)	1.1 (0.2)	2.6 (1.2)	0.9 (0.5)	1.5 (0.8)	1.8 (1.0)	2.7 (1.6)	2.2 (1.3)	1.7 (1.0)	1.3 (1.7)	1.0 (0.8)	1.7 (1.6)
Number of counsenor interactions	Median [Q1, Q3]	3 [2, 3]	1 [1, 1]	3 [2, 4]	1 [1, 1]	1 [1, 2]	2 [1, 2]	2 [2, 4]	2 [1, 3]	1 [1, 2]	1 [0, 1]	1 [0.3, 1]	1 [1, 2]
Drugs, medications or devices dispe	nsed												
	Mean (SD)	130.0 (62.8)	32.9 (16.9)	119.0 (59.6)	30.6 (4.12)	68.3 (58.9)	79.6 (63.1)	79.6 (54.1)	66.0 (44.3)	57.8 (42.5)	65.2 (65.3)	37.4 (19.7)	64.5 (55.3)
Days of PrEP dispensed	Median	120	30	120	30	30	59	60	60	30	30	30	30
	[Q1, Q3]	[120, 186]	[30, 30]	[60, 163]	[30, 30]	[30, 120]	[30, 120]	[30, 120]	[30, 90]	[30, 90]	[30, 90]	[30, 30]	[30, 90]
Number of PrEP-clients who had	n (%)	4 (4.1%)	0 (0.0%)	15 (14.7%)	2 (3.8%)	18 (18.8%)	19 (19.4%)	10 (23.8%)	14 (14.1%)	32 (33.3%)	7 (4.2%)	0 (0.0%)	0 (0.0%)
STI medication dispensed ^a	II (70)	+ (+.170)	0 (0.070)	15 (14.770)	2 (3.070)	10 (10.070)	17 (17.470)	10 (25.070)	14 (14.170)	52 (55.570)	7 (4.270)	0 (0.070)	0 (0.070)
Number of PrEP-clients who had	n (%)	5 (5.1%)	0 (0.0%)	20 (19.6%)	2 (3.8%)	26 (27.1%)	41 (41.8%)	21 (50.0%)	42 (42.4%)	53 (55.2%)	9 (5.4%)	2 (2.2%)	0 (0.0%)
any other medication dispensed ^b	n (70)	5 (5.170)	0 (0.070)	20 (19.070)	2 (3.070)	20 (27:170)	41 (41.070)	21 (50.070)	42 (42:470)	55 (55.270)) (3.470)	2 (2:270)	0 (0.070)
Laboratory tests conducted													
HIV test	Mean (SD)	2.0 (1.0)	1.0 (0.2)	2.6 (1.2)	1.0 (0.2)	1.4 (0.7)	1.7 (1.0)	2.2 (1.2)	1.9 (1.1)	1.6 (1.0)	1.9 (1.5)	1.3 (0.6)	1.6 (1.1)
Creatinine test	Mean (SD)	1.2 (1.0)	1.0 (0.2)	1.0 (0.7)	0.2 (0.5)	1.2 (0.6)	1.2 (0.6)	1.6 (0.7)	1.4 (0.7)	0.8 (0.5)	1.0 (0.4)	0.8 (0.5)	1.0 (0.3)
HBsAg test ^c	Mean (SD)	0.0 (0.0)	0.0 (0.0)	0.2 (0.5)	0.0 (0.1)	0.0 (0.1)	0.0 (0.1)	0.1 (0.4)	0.0 (0.2)	0.0 (0.0)	0.7 (0.5)	0.5 (0.5)	0.0 (0.1)
HBsAb test ^d	Mean (SD)	0.0 (0.0)	0.0 (0.0)	0.9 (0.6)	0.1 (0.3)	0.8 (0.6)	0.9 (0.4)	0.9 (0.5)	0.8 (0.4)	0.8 (0.5)	1.0 (0.3)	0.7 (0.4)	1.0 (0.2)
Syphilis rapid test	Mean (SD)	0.0 (0.2)	0.0 (0.0)	0.5 (0.9)	0.1 (0.4)	0.5 (0.5)	0.5 (0.5)	0.9 (0.4)	0.8 (0.5)	0.0 (0.1)	0.9 (0.3)	0.7 (0.4)	0.9 (0.3)
Pregnancy test	Mean (SD)	0.0 (0.0)	0.0 (0.0)	0.0 (0.0)	0.0 (0.0)	0.1 (0.4)	0.3 (0.8)	0.5 (0.9)	0.4 (0.9)	1.2 (0.9)	1.3 (1.4)	0.7 (0.8)	0.9 (0.4)
Other ^e	Mean (SD)	0.2 (0.4)	0.0 (0.0)	0.5 (0.7)	0.2 (0.4)	0.2 (0.5)	0.1 (0.4)	0.2 (0.4)	0.1 (0.3)	0.0 (0.0)	0.0 (0.2)	0.1 (0.3)	0.0 (0.0)

^aSTI medications include: Ceftriaxone, Cefuroxime, Metronidazle, Doxycycline, Azithromycin, Benzathine Penicillin, Flucloxacillin and Acyclovir.

^bOther medications include: Paracetamol, Ibuprofen, Diclofenac, Amlodipine, Augmentin, Ciprofloxacin, Bactrim, Allergex, Amoxicillin, Illiadin, Combined Oral contraceptives, Progesterone injection, Saline nasal spray.

^cHepatitis B surface antigen

^dHepatitis B antibody to surface antigen

°Other laboratory tests conducted include: AST, ALT, Hb, Urine dipstix, Papsmear, Hepatitis A IgM, Hepatitis C Antibody, GeneXpert

7 <u>Table 6: Six- and 12-month outcomes by site and service delivery model</u>

		MSM	Site 1	MSM	Site 2	FSW	Site 1	FSW	Site 2	FSW Site 3	AGYW	Site 1	AGYW Site 2	Ove	erall
		In facility	Outreach	In facility	Outreach	In facility	Outreach	In facility	Outreach	Outreach	In facility	Outreach	In facility	In facility	Outreach
6-month cohort (n=1281)		(N=98)	(N=139)	(N=102)	(N=53)	(N=96)	(N=98)	(N=42)	(N=99)	(N=96)	(N=168)	(N=90)	(N=200)	(N=706)	(N=575)
Same-day PrEP initiation	Yes (%)	32 (32.7%)	135 (97.1%)	100 (98.0%)	50 (94.3%)	92 (95.8%)	97 (99.0%)	42 (100%)	98 (99.0%)	96 (100%)	164 (97.6%)	89 (98.9%)	196 (98.0%)	626 (88.7%)	565 (98.3%)
PrEP-client had at least one follow up visit ^a	Yes (%)	82 (83.7%)	6 (4.3%)	82 (80.4%)	1 (1.9%)	35 (36.5%)	53 (54.1%)	33 (78.6%)	58 (58.6%)	38 (39.6%)	68 (40.5%)	16 (17.8%)	76 (38.0%)	376 (53.3%)	172 (29.9%)
Time between PrEP	Mean (SD)	31.2 (21.6)	71.8 (56.5)	32.0 (18.1)	NA	59.1 (45.4)	67.3 (51.4)	48.4 (32.2)	49.6 (36.6)	62.0 (36.3)	36.6 (25.4)	55.2 (49.0)	36.8 (17.4)	37.5 (26.3)	58.8 (43.7)
initiation and first follow-up (days) ^b	Median (IQR)	25.0 [21.0,29.8]	48.5 [43.5, 83.5]	28.0 [27.0, 29.0]	0.0 [0.0, 0.0]	35.0 [28.0,74.0]	29.0 [28.0,115.0]	32.0 [28.0,59.0]	28.0 [28.0,77.8]	58.5 [28.0,83.5]	28.0 [28.0,33.0]	34.5 [28.0,55.8]	28.0 [28.0,37.0]	28.0 [27.0, 34.0]	33.0 [28.0, 84.5]
Time in care at 6	Mean (SD)	132 (57.4)	36.1 (25.0)	128 (59.8)	32.3 (9.88)	97.0 (54.7)	108 (60.9)	121 (63.3)	90.3 (63.9)	78.3 (60.9)	72.5 (61.4)	47.4 (44.2)	70.1 (59.5)	94.3 (64.6)	66.2 (56.6)
months (days) ^c	Median (IQR)	142 [104, 183]	30.0 [30.0, 30.0]	146 [67.3, 183]	30.0 [30.0, 30.0]	90.0 [30.0, 144]	116 [30.0, 183]	143 [58.3, 183]	58.0 [30.0, 166]	30.0 [30.0, 136]	30.0 [30.0,118]	30.0 [30.0,30.0]	30.0 [30.0,92.5]	88.0 [30.0, 182]	30.0 [30.0, 90.0]
Engaged in care ^d	At 3 months (%)	55 (56.1%)	4 (2.9%)	53 (52.0%)	0 (0%)	29 (30.2%)	41 (41.8%)	30 (71.4%)	38 (38.4%)	22 (22.9%)	40 (23.8%)	11 (12.2%)	41 (20.5%)	248 (35.1%)	116 (20.2%)
PrEP coverage ^e	At 3 months (%)	78 (79.6%)	6 (4.3%)	69 (67.6%)	0 (0%)	36 (37.5%)	52 (53.1%)	25 (59.5%)	38 (38.4%)	33 (34.4%)	48 (28.6%)	9 (10.0%)	51 (25.5%)	307 (43.5%)	138 (24.0%)
TTER coverage	At 6 months (%)	41 (41.8%)	1 (0.7%)	38 (37.3%)	0 (0%)	13 (13.5%)	22 (22.4%)	9 (21.4%)	13 (13.1%)	9 (9.4%)	22 (13.1%)	4 (4.4%)	31 (15.5%)	154 (21.8%)	49 (8.5%)
	Death (%) HIV seroconversion	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Reason for not being	(%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	2 (4.8%)	0 (0%)	0 (0%)	1 (0.6%)	0 (0%)	0 (0%)	3 (0.4%)	0 (0%)
covered with PrEP at 6 months ^f	Reported as having stopped PrEP (%)	2 (2.0%)	1 (0.7%)	1 (1.0%)	5 (9.4%)	1 (1.0%)	3 (3.1%)	2 (4.8%)	5 (5.1%)	1 (1.0%)	1 (0.6%)	1 (1.1%)	7 (3.5%)	14 (2.0%)	16 (2.8%)
	Reason unknown (%)	33 (33.7%)	21 (15.1%)	15 (14.7%)	45 (84.9%)	41 (42.7%)	53 (54.1%)	6 (14.3%)	12 (12.1%)	51 (53.1%)	105 (62.5%)	39 (43.3%)	61 (30.5%)	261 (37.0%)	221 (38.4%)
12-month cohort (n=633)		(N=97)	(N=71)	(N=0)	(N=0)	(N=93)	(N=98)	(N=41)	(N=99)	(N=0)	(N=68)	(N=66)	(N=0)	(N=299)	(N=334)
Same-day PrEP initiation	Yes (%)	32 (33.0%)	68 (95.8%)	-	-	90 (96.8%)	97 (99.0%)	41 (100%)	98 (99.0%)	-	66 (97.1%)	66 (100%)	-	229 (76.6%)	329 (98.5%)
PrEP-client had at least one follow up visit ^a	Yes (%)	83 (85.6%)	6 (8.5%)	-	-	37 (39.8%)	58 (59.2%)	37 (90.2%)	59 (59.6%)	-	27 (39.7%)	14 (21.2%)	-	184 (61.5%)	137 (41.0%)
Time between PrEP	Mean (SD)	32.3 (30.1)	71.8 (56.5)	-	-	79.3 (75.0)	80.5 (68.9)	79.4 (78.9)	52.1 (41.0)	-	49.5 (50.5)	102 (114)	-	53.7 (59.8)	70.1 (66.1)
initiation and first follow-up (days) ^b	Median (IQR)	25.0 [21.0, 29.5]	48.5 [43.5, 83.5]	-	-	41.0 [28.0, 111]	29.5 [28.0, 127]	34.0 [29.0, 96.0]	28.0 [28.0, 83.5]	-	29.0 [28.0, 37.5]	35.0 [28.0, 149]	-	29.0 [25.0, 49.3]	31.0 [28.0, 106]
Time in care at 12	Mean (SD)	220 (133)	41 (42)	-	-	122 (126)	155 (129)	221 (127)	137 (128)	-	88 (104)	69 (95)	-	160 (136)	108 (118)
months (days) ^c	Median (IQR)	201 [113, 365]	30 [30, 30]	-	-	30 [30, 209]	118 [30, 262]	227 [114, 352]	58 [30, 259]	-	30 [30,98]	30 [30,30]	-	114 [30, 320]	30 [30, 146]
Engaged in care ^d	At 9 months (%)	38 (39.2%)	0 (0%)	-	-	12 (12.9%)	16 (16.3%)	15 (36.6%)	17 (17.2%)	-	6 (8.8%)	4 (6.1%)	-	71 (23.7%)	37 (11.1%)
PrEP coverage ^e	At 9 months (%)	(45.4%)	1 (1.4%)	-	-	(22.6%)	22 (22.4%)	18 (43.9%)	24 (24.2%)	-	8 (11.8%)	6 (9.1%)	-	91 (30.4%)	53 (15.9%)
	At 12 months (%)	34 (35.1%)	0 (0%)	-	-	9 (9.7%)	15 (15.3%)	8 (19.5%)	13 (13.1%)	-	3 (4.4%)	4 (6.1%)	-	54 (18.1%)	32 (9.6%)
	Death (%)	0 (0%)	0 (0%)	-	-	0 (0%)	0 (0%)	0 (0%)	0 (0%)	-	0 (0%)	0 (0%)	-	0 (0%)	0 (0%)
Reason for not being covered with PrEP at	HIV seroconversion (%)	0 (0%)	0 (0%)	-	-	0 (0%)	0 (0%)	2 (6.1%)	0 (0%)	-	1 (1.5%)	0 (0%)	-	3 (1.2%)	0 (0%)
12 months ^f	Reported as having stopped PrEP (%)	1 (1.6%)	1 (1.4%)	-	-	1 (1.2%)	4 (4.8%)	4 (12.1%)	4 (4.7%)	-	1 (1.5%)	1 (1.6%)	-	7 (2.9%)	10 (3.3%)

Reason unknown (%)	62 (98.4%)	70 (98.6%)	-	- (9	83 3.8%)	79 (95.2%)	27 (81.8%)	82 (95.3%)	-	63 (96.9%)	61 (98.4%)	-	235 (95.9%)	292 (96.7%)
to the DrCD initiation visit the DrCD client has	d at laast ana a	ببر المعرفة الم	ithin the time period (C m	anths or 12 m	nthe)									I

aln addition to the PrEP initiation visit, the PrEP client had at least one additional visit within the time period (6 months or 12 months).

^bAmong those who had at least one follow up visit within the time period (6 months or 12 months).

cTotal number of PrEP tablets dispensed excluding any over dispensing at the last visit - capped at the maximum follow up period (180 or 365).

^dAttended a visit at or past stipulated time period following PrEP initiation.

eAt the PrEP client's last visit in the follow up period, they were dispensed sufficient drug to cover them to the end of the follow up period.

fAmong those who were not dispensed sufficient drug to cover them to the end of the follow up period.

Abbreviations: MSM: men-who-have-sex-with-men; FSW: female sex workers; AGYW: adolescent girls and young women; IQR: interquartile range.

	MSM	Site 1	MSM Site 2		FSW	Site 1	FSW S	ite 2	FSW Site 3	AGYW Site 1		AGYW Site 2
Service delivery model	In- facility	Outreach	In- facility	Outreach	In- facility	Outreach	In-facility	Outreach	Outreach	In- facility	Outreach	In-facility
Proportion of clients with PrEP coverage at 6 months	41/98 (41.8%)	1/139 (0.7%)	38/102 (37.3%)	0/53 (0%)	13/96 (13.5%)	22/98 (22.4%)	9/42 (21.4%)	13/99 (13.1%)	9/96 (9.4%)	22/168 (13.1%)	4/90 (4.4%)	31/200 (15.5%)
Average 6-month cost per PrEP-client	:											
All PrEP-clients	228 (208- 248)	76 (73-79)	191 (175- 208)	29 (26-31)	125 (111- 140)	75 (68-83)	590 (488-692)	105 (93-117)	131 (116-147)	84 (76-92)	61 (55-68)	73 (66-80)
PrEP clients with PrEP coverage at 6 months	312 (293- 332)	140	248 (236- 262)	-	236 (204- 268)	108 (92-125)	959 (753-1164)	220 (190- 250)	276 (231-320)	179 (155- 203)	132 (43-220)	170 (160-181)
Average cost per person-month per P	rEP-client ^a											
All PrEP-clients	58 (53-63)	71 (70-73)	53 (49-58)	28 (26-31)	68 (62-74)	32 (29-34)	182 (159-204)	44 (41-47)	66 (62-70)	47 (42-52)	48 (45-51)	37 (36-39)
PrEP clients with PrEP coverage at 6 months	52 (49-55)	23	142 (39-44)	-	39 (34-45)	18 (15-21)	160 (126-195)	37 (32-42)	46 (39-53)	30 (26-34)	22 (7-39)	28 (27-30)
Cost breakdown for PrEP-clients with	PrEP cover	age at 6 month										
Drugs	26 (24-28)	5	24 (23-26)	-	13 (13-13)	18 (14-22)	20 (13-26)	21 (17-25)	16 (11-21)	24 (17-31)	10 (1-19)	24 (22-26)
Lab tests	16 (14-19)	12	35 (30-39)	-	31 (24-38)	26 (21-30)	32 (28-37)	33 (27-39)	28 (23-34)	43 (38-49)	35 (6-63)	28 (25-30)
Clinic staff visit cost	133 (124- 142)	47	127 (120- 135)	-	89 (77-102)	15 (13-17)	744 (573-915)	60 (51-69)	23 (19-28)	69 (56-82)	45 (17-73)	61 (57-65)
Fixed costs (buildings, equipment, management, admin)	136 (128- 146)	75	63 (58-67)	-	103 (89-117)	50 (43-57)	163 (130-196)	107 (90-124)	208 (170-245)	42 (37-48)	42 (16-67)	58 (54-62)
Production cost of PrEP coverage at 6 months	545	10,537	514	-	929	336	2,754	780	1,403	643	1,379	470

Table 7: Estimated costs per PrEP-client of six months of PrEP provision by site and service delivery model. Costs reported in 2021 USD (95% CD) 15

19

20

All rights reserved. No reuse allowed without permission.

22 References

1. UNAIDS. UNAIDS Data 2021 2021 [Available from: 23 https://www.unaids.org/sites/default/files/media asset/JC3032 AIDS Data book 2021 En.pdf. 24 25 2. UNAIDS. UNAIDS Data 2022 2022 [Available from: https://www.unaids.org/sites/default/files/media_asset/data-book-2022_en.pdf. 26 UNAIDS. UNAIDS Factsheet 2022. 2022. 27 3. United Nations General Assembly. Resolution adopted by the General Assembly on 8 June 2016. 28 4. 29 70/266 Political Declaration on HIV and AIDS: On the Fast Track to Accelerating the Fight against HIV and 30 to Ending the AIDS Epidemic by 2030. 97th plenary meeting; 2016 8 June 2016. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral Prophylaxis 31 5. for HIV Prevention in Heterosexual Men and Women. NEW ENGLAND JOURNAL OF MEDICINE. 32 33 2012;367(5):399-410. UNAIDS. Global AIDS Update 2021 2021 [Available from: 34 6. 35 https://www.unaids.org/sites/default/files/media asset/JC3032 AIDS Data book 2021 En.pdf. World Health Organization. Policy brief: pre-exposure prophylaxis (PrEP): WHO expands 36 7. recommendation on oral pre-exposure prophylaxis of HIV infection (PrEP). Geneva: World Health 37 38 Organization; 2015 2015. Contract No.: WHO/HIV/2015.48. Case KK, Gomez GB, Hallett TB. The impact, cost and cost-effectiveness of oral pre-exposure 39 8. prophylaxis in sub-Saharan Africa: a scoping review of modelling contributions and way forward. Journal of 40 41 the International AIDS Society. 2019;22(9):e25390. 42 Bershteyn A, Sharma M, Akullian AN, Peebles K, Sarkar S, Braithwaite RS, et al. Impact along the 9. 43 HIV pre-exposure prophylaxis "cascade of prevention" in western Kenya: a mathematical modelling study. 44 Journal of the International AIDS Society. 2020;23 Suppl 3(Suppl 3):e25527. Pretorius C, Schnure M, Dent J, Glaubius R, Mahiane G, Hamilton M, et al. Modelling impact and 45 10. cost-effectiveness of oral pre-exposure prophylaxis in 13 low-resource countries. Journal of the International 46 47 AIDS Society. 2020;23(2). 11. Price JT, Wheeler SB, Stranix-Chibanda L, Hosek SG, Watts DH, Siberry GK, et al. Cost-48 49 Effectiveness of Pre-exposure HIV Prophylaxis During Pregnancy and Breastfeeding in Sub-Saharan Africa. J Acquir Immune Defic Syndr. 2016;72 Suppl 2(Suppl 2):S145-53. 50 51 Phillips AN, Bershteyn, A., Revill, P., Bansi-Matharu, L., Kripke, K., Boily, M. C., Martin-Hughes, 12. 52 R., Johnson, L. F., Mukandavire, Z., Jamieson, L., Meyer-Rath, G., Hallett, T. B., Ten Brink, D., Kelly, S. L., Nichols, B. E., Bendavid, E., Mudimu, E., Taramusi, I., Smith, J., Dalal, S., Baggaley, R., Crowley, Terris-53 Prestholt, F., Godfrey-Faussett, P., Mukui, I., Jahn, A., Case, K. K., Havlir, D., Petersen, M., Kamya, M., 54 55 Koss, C. A., Balzer, L. B., Apollo, T., Chidarikire, T., Mellors, J. W., Parikh, U. M., Godfrey, C., Cambiano, 56 V. Cost-effectiveness of easy-access, risk-informed oral pre-exposure prophylaxis in HIV epidemics in sub-57 Saharan Africa: a modelling study. The lancet HIV. 2022;9(5):e353-e62. Nichols BE, Baltussen R, van Dijk JH, Thuma PE, Nouwen JL, Boucher CA, et al. Cost-effectiveness 58 13. of PrEP in HIV/AIDS control in Zambia: a stochastic league approach. J Acquir Immune Defic Syndr. 59 60 2014;66(2):221-8. Nichols BE, Boucher CA, van Dijk JH, Thuma PE, Nouwen JL, Baltussen R, et al. Cost-effectiveness 14. 61 of pre-exposure prophylaxis (PrEP) in preventing HIV-1 infections in rural Zambia: a modeling study. PLoS 62 63 One. 2013;8(3):e59549. Alistar SS, Grant PM, Bendavid E. Comparative effectiveness and cost-effectiveness of antiretroviral 64 15. therapy and pre-exposure prophylaxis for HIV prevention in South Africa. BMC medicine. 2014;12:46. 65 Jamieson L, Gomez GB, Rebe K, Brown B, Subedar H, Jenkins S, et al. The impact of self-selection 66 16. based on HIV risk on the cost-effectiveness of preexposure prophylaxis in South Africa. Aids. 67 68 2020;34(6):883-91. van Vliet MM, Hendrickson C, Nichols BE, Boucher CA, Peters RP, van de Vijver DA. 69 17. Epidemiological impact and cost-effectiveness of providing long-acting pre-exposure prophylaxis to 70 injectable contraceptive users for HIV prevention in South Africa: a modelling study. Journal of the 71 72 International AIDS Society. 2019;22(12):e25427. 73 Vogelzang M, Terris-Prestholt F, Vickerman P, Delany-Moretlwe S, Travill D, Quaife M. Cost-18. 74 Effectiveness of HIV Pre-exposure Prophylaxis Among Heterosexual Men in South Africa: A Cost-Utility 75 Modeling Analysis. J Acquir Immune Defic Syndr. 2020;84(2):173-81.

- medRxiv preprint doi: https://doi.org/10.1101/2023.08.14.23294055; this version posted August 16, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. 19. Walensky RP, Park JE, Wood R, Freedberg KA, Scott CA, Bekker LG, et al. The cost-effectiveness 76 77 of pre-exposure prophylaxis for HIV infection in South African women. Clinical Infectious Diseases. 78 2012;54(10):1504-13. 79 Phillips AN, Cambiano V, Johnson L, Nakagawa F, Homan R, Meyer-Rath G, et al. Potential Impact 20. and Cost-Effectiveness of Condomless-Sex-Concentrated PrEP in KwaZulu-Natal Accounting for Drug 80 Resistance. The Journal of infectious diseases. 2021;223(8):1345-55. 81 South African Department of Health. Guidelines for the provision of pre-exposure prophylaxis (PrEP) 82 21. to persons at substantial risk of HIV infection. 2020. 83 Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, et al. The REDCap consortium: 22. 84 Building an international community of software platform partners. J Biomed Inform. 2019:95:103208. 85 Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture 86 23. (REDCap)—a metadata-driven methodology and workflow process for providing translational research 87 88 informatics support. Journal of biomedical informatics. 2009;42(2):377-81. 24. Bill and Melinda Gates Foundation. Global Health Cost Consortium [Available from: 89 90 https://ghcosting.org/ 91 25. Vassall A, Sweeney, S., Kahn, J.G., Gomez, G., Bollinger, L., Marseille, E., Herzel, B., DeCormier 92 Plosky, W., Cunnama, L., Sinanovic, E., Bautista, S., GHCC Technical Advisory Group, GHCC Stakeholder 93 Group, Harris, K., Lev C. Reference Case for Estimating the Costs of Global Health Services and 94 Interventions. 2017. Statistics South Africa. Consumer Price Index (CPI), March 2022 2022 [Available from: 95 26. https://www.statssa.gov.za/?page id=1854&PPN=P0141&SCH=73029. 96 97 27. Earnst and Young. Worldwide Capital and Fixed Assets Guide. 2018. 98 28. Long L, Rosen, S., Girdwood, S. The Healthcare Cost and Outcomes Model. 2017. Peebles K, Mugwanya KK, Irungu E, Odoyo J, Wamoni E, Morton JF, et al. Low costs and 99 29. opportunities for efficiency: a cost analysis of the first year of programmatic PrEP delivery in Kenya's public 100 sector. BMC health services research. 2021;21(1):823. 101 Roberts DA, Barnabas RV, Abuna F, Lagat H, Kinuthia J, Pintye J, et al. The role of costing in the 102 30. introduction and scale-up of HIV pre-exposure prophylaxis: evidence from integrating PrEP into routine 103 104 maternal and child health and family planning clinics in western Kenya. Journal of the International AIDS Society. 2019;22 Suppl 4:e25296. 105 Wanga V, Peebles K, Obiero A, Mogaka F, Omollo V, Odovo JB, et al. Cost of pre-exposure 106 31. 107 prophylaxis delivery in family planning clinics to prevent HIV acquisition among adolescent girls and young women in Kisumu, Kenya. PLoS One. 2021;16(4):e0249625. 108 Meyer-Rath G, van Rensburg C, Chiu C, Leuner R, Jamieson L, Cohen S. The per-patient costs of 109 32. 110 HIV services in South Africa: Systematic review and application in the South African HIV Investment Case. PLoS One. 2019;14(2):e0210497. 111 Eakle R, Gomez GB, Naicker N, Bothma R, Mbogua J, Cabrera Escobar MA, et al. HIV pre-exposure 112 33.
- Bakle R, Gomez GB, Naicker N, Bothma R, Mbogua J, Cabrera Escobar MA, et al. HIV pre-exposure
 prophylaxis and early antiretroviral treatment among female sex workers in South Africa: Results from a
 prospective observational demonstration project. PLoS medicine. 2017;14(11):e1002444.
- Irungu EM, Sharma M, Maronga C, Mugo N, Ngure K, Celum C, et al. The Incremental Cost of
 Delivering PrEP as a Bridge to ART for HIV Serodiscordant Couples in Public HIV Care Clinics in Kenya.
 AIDS research and treatment. 2019;2019:4170615.
- Mangenah C, Nhamo D, Gudukeya S, Gwavava E, Gavi C, Chiwawa P, et al. Efficiency in PrEP
 Delivery: Estimating the Annual Costs of Oral PrEP in Zimbabwe. AIDS and behavior. 2021.
- 120 36. Mutuku U, Forsythe, S., Glaubius, R., Were, D., Musau, A. Estimating the Costs of PrE-exposure 121 Prophylaxis (PrEP) in Ten Counties of Kenya. International Conference for AIDS and STIs in Africa2019.
- 37. Peebles K, Mugwanya KK, Irungu E, Odoyo J, Wamoni E, Morton JF, et al. Low costs and
 opportunities for efficiency: a cost analysis of the first year of programmatic PrEP delivery in Kenya's public
 sector. BMC health services research. 2021;21(1):823.
- 125 38. Roberts A, Barnabas, RV., Abuna, F., Lagat, H., Kinuthia, J., Pintye, J., Bochner, A., Baeten, J.,
- John-Stewart, G., Levine, C. The Cost of PrEP Delivery in Kenyan Antenatal, Postnatal, and Family
- Planning Clinics. Conference on Retroviruses and Opportunistic Infections; March 4-7 2019; Seattle, WA,
 USA2019.

129 39. Ying R, Sharma M, Heffron R, Celum CL, Baeten JM, Katabira E, et al. Cost-effectiveness of pre-130 exposure prophylaxis targeted to high-risk serodiscordant couples as a bridge to sustained ART use in

Kampala, Uganda. Journal of the International AIDS Society. 2015;18(4 Suppl 3):20013. 131

132 Mudimu E, Sardinia J, Momin S, Medina-Marino A, Bezuidenhout C, Bekker LG, et al. Incremental 40.

133 costs of integrated PrEP provision and effective use counselling in community-based platforms for

134 adolescent girls and young women in South Africa: an observational study. Journal of the International AIDS 135 Society. 2022;25(2):e25875.